Curis | CRIS - Assets


Curis reported $29.69M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Curis USD 29.69M 9.72M Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Verastem USD 227.81M 18.63M Mar/2026